Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commercial efforts with pipeline renewal and maintenance.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Meet Marty Deere And Resmetirom
- 3:40From Banking To Biotech IR
- 8:56Big Biotech Lessons At Chiron
- 11:59Portola’s Capital Strategy In A Crisis
- 19:15Choosing The IPO Window
- 24:24Acquisition Dynamics And Launch Risks
- 30:20Ultragenyx And The Acceleron Playbook
- 36:10Joining Madrigal On The Cusp Of Approval
- 42:20Building A Commercial Culture Fast